Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/50/d1/f3/50d1f3a4-9196-99af-e606-32fac886fb2b/mza_14611349014101973697.jpg/600x600bb.jpg
MDS Professional Report
MDS Foundation
13 episodes
3 weeks ago
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research.
The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
Show more...
Medicine
Health & Fitness
RSS
All content for MDS Professional Report is the property of MDS Foundation and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research.
The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
Show more...
Medicine
Health & Fitness
https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/7b8bc7d62bbbfefa1a0c2f97a3d163fe.jpg
TP53 mutations – were they born equal [MDS Professional Report]
MDS Professional Report
28 minutes
4 years ago
TP53 mutations – were they born equal [MDS Professional Report]
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is: not all of them are infeed associated with poor prognosis.
Sallman DA et al:A recent study led by Dr. David Sallman tested the efficacy of the combination azacitidine and eprenetapopt (formerly APR-246), a TP53-Mutant activator, in patients with higher-risk MDS.
Goll JB et al:One of the more interesting presentations in the last ASH 2020, was that of Dr. Yohannes Goll and others. They showed that adding molecular analysis they can improve the diagnostic accuracy. Indeed 7 genes significantly reduced pathological misclassification.
Platzbecker U et al:A group of international investigators, led by Dr. Uwe Platzbecker, from Leipzig, reported in last ASH (2020) their encouraging experience with imetelstat, a telomerase-inhibitor to improve anemia in lower-risk MDS patients after ESA failure.
MDS Professional Report
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research.
The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.